The International Glaucoma Association operating as **Glaucoma UK** 

## Report and Financial Statements **for the year ending 31 July 2022** 




**2021/22** 



**Page** 

|||
|---|---|
|**Contents**|**Pag**|
|**Welcome from the Chair**|**2**|
|**Our Vision and Objectives**|**3**|
|**How Our Support Counted in 2021/22**|**6**|
|**Strategic Report - Performance and Achievement**|**7**|
|Campaigning and Raising Awareness|7|
|Providing Advice and Support|12|
|Funding Research|18|
|**Fundraising Review**|**20**|
|**Looking Forward**|**22**|
|**Our Finances**|**23**|
|Financial Review|23|
|Reserves Policy|24|
|Going Concern|25|
|Investment Policy|26|
|**Governance and Leadership**|**27**|
|Trustees, Advisors and Staff|27|
|Structure and Management|28|
|The Board and Committees|28|
|Statement of Public Benefit|29|
|Related Parties and Connected Charities|29|
|Risk Management and Internal Control|30|
|Remuneration Policy|31|
|Statement of Trustee Responsibilities|32|
|**Independent Auditor’s Report**|**33**|
|**Financial Statements**|**36**|



Page **1** 



## **Welcome from the Chair** 


**Professor Anthony King,** Consultant Ophthalmologist and Glaucoma UK Chair 

**It is a pleasure and a privilege to have taken over as Chair at Glaucoma UK at such an exciting time. Having invested in additional staff capacity for community work, professional engagement and data insight, we are in a great position to understand where our work makes the most difference… and do more of it.”** 

As I seek to help guide the charity, I am very conscious that I am building upon the excellent work of my predecessor, Professor Philip Bloom, who was a Trustee for seven years and went on to lead the organisation as Chair for a further five. His energy and commitment were integral to the charity’s development during that time and his extensive professional knowledge and expertise proved invaluable. 

Similarly, we also said goodbye to our Chief Executive Officer (CEO), Karen Osborn, in January 2022. During her five years with Glaucoma UK, Karen worked tirelessly to improve processes and ensure the charity was in the best possible shape to expand its reach and help more people. I extend my thanks to Philip, to Karen and also to Claire Cardy, who served us with enormous energy and commitment as interim CEO between January and April 2022. I look forward to working with our new CEO, Joanne Creighton, as we seek to play our parts in taking the organisation forward. 

Having been a trustee of Glaucoma UK for five years, I am well aware of the extraordinary, mutually supportive community that surrounds the charity. And the members of that community are absolutely at the heart of this report. We simply could not do what we do without the generosity of our donors, the loyalty of our membership, the dedication of our staff and volunteers, the tireless efforts of those who fundraise for us and the knowledge and commitment of our Board and Clinical Advisory Panel. I thank them – one and all – for all they do, year after year, to make this a charity of which we can all feel very proud. 

Page **2** 




## **Our Vision and Objectives** 

## **What is glaucoma?** 

Glaucoma is a complicated group of eye diseases that damage the optic nerve. Left untreated, glaucoma will lead to irreversible sight loss and even blindness. 

Most people experience no symptoms in the early stages and most glaucoma is picked up during a routine eye examination. 

Over 700,000 people in the UK are affected by glaucoma and it is estimated that almost half of those are unaware they are living with the disease. This is because almost a third of the adult population is failing to have an eye test every two years as recommended, despite research telling us that sight is the sense people most fear to lose. Getting that message across is crucial, as early detection and appropriate treatment will enable most people with glaucoma to retain useful sight for life. 

## **What can Glaucoma UK do to help?** 

Glaucoma UK is a membership charity with over 4,000 members, including those living with glaucoma and the professionals who support them. Although members benefit from our quarterly ‘Insight’ magazine, support is provided free of charge to anyone who needs it and you do not need to be a member to access our services. 

People with, or at risk from, glaucoma and related conditions are at the heart of our activities and we aim to represent their views at national level and tailor our services to their support and information needs. Services we provide include a helpline, information guides and leaflets, online webinars, face-to-face support groups and events, as well as professional support for those working in glaucoma treatment and care. 

## **What are the challenges we face?** 

Research from the Royal College of Ophthalmologists has shown that the number of people with glaucoma is increasing due to the ageing population. One in 10 people aged 75 or over are affected by glaucoma and the total number of people living with glaucoma in the UK is expected to increase by nearly a third between 2020 and 2035. And with ophthalmology services experiencing the greatest post-COVID backlog of any NHS specialty, the pressures on glaucoma detection, treatment and monitoring have never been greater. 

Page **3** 



There is a particular need to help raise awareness among those groups who are at highest risk of developing the disease, including people with a family history of glaucoma and people of African-Caribbean origin. Work is also required to tackle the impact of health inequalities in glaucoma care, especially the increased prevalence of undetected cases in areas of social deprivation. 

## **Our vision** 

At Glaucoma UK, our vision is an end to preventable glaucoma sight loss. 

## **Our strategic objectives** 

In working towards our vision, three areas of strategic focus underpin our work: 


## **1. Campaigning and awareness** 

We want everyone in the UK who is living with glaucoma to receive swift and appropriate treatment. Our principal objective is to encourage people to have their eyes tested every two years, unless advised otherwise by their healthcare professional. 

We want the voice of people living with glaucoma to be heard by those who provide treatment, design care pathways and commission services. 


Page **4** 



## **2. Providing advice and support** 

We want those living with glaucoma to have the support they need to live well. Lifelong glaucoma treatment can be complex and challenging, with some individuals finding the treatment worse than the disease itself. Many do not fully understand glaucoma, which means that making choices and effectively managing their treatment can be difficult. At Glaucoma UK, we want to address this information gap with the right help and advice, delivered in the right way, at the right time. 

We want all those involved in delivering glaucoma care to have up-to-date information and access to effective professional networks for sharing best practice. Through our administration and support for the United Kingdom and Éire Glaucoma Society (UKEGS) – which became part of Glaucoma UK in 2019 – we want to bring together scientists and clinicians in a vibrant, aspirational scientific community. Through the work of our Professional Engagement Leads we play a key role in making connections that can help to promote, protect and safeguard the interests of people living with - or at risk of - glaucoma. 

## **3. Funding research** 

We want to understand what causes glaucoma, how it can be prevented, what are the most effective treatments and – ultimately – how it could be cured. High quality research is needed to end glaucoma sight loss, so we are committed to funding studies that will help to test new medical and surgical models and explore new ways of working. By funding the Professor of Ophthalmology at University College London and working with partners including the Royal College of Ophthalmologists and the charity ‘Fight for Sight’, we aim to deliver a research programme that will have a real impact for the people we serve - now and in the future. 


Page **5** 



How our support
counted in 2021122
This year we have provided
329,527 instances of support.
Our highlights included:
90,819
A30%
Booklets provided
(82% of these were for
the NHS)
5,737A25%
717
A18%
Digital glaucoma
SUPPOrt group
attendees.
Healthunlocked posts
and responses
67
22Yo
Buddy pairings
189,710
A33Yo
Views of our website
support pages
2,352A420
Helpline enquiries
AX% means increase on previousyear
Data covers 01.08.2021- 31.07.2022
* Comparative data for face-to-face glaucoma support groups
is unavailable due to COVID-19's impact on this service.


## **Strategic Report 2021/22 – Performance and Achievement** 

## **Campaigning and Raising Awareness** 

Our main priority for the year was to continue to develop and deliver our data-driven communication strategy to ensure that our key messages achieved maximum impact and value for money. 

## **Using data insights** 

With the help of our new Data Insight Lead, we have developed a new analytics dashboard which brings together information from a range of sources and provides important live data. Alongside being used for impact reporting, the dashboard enables us to identify and respond quickly to unusual patterns of activity on our digital platforms such as bot activity which could be harmful or distort our reporting. 

We also invested in a new software tool that gives us visual insights into how people are navigating and using our website. This information has allowed our communications team to identify opportunities for optimisation and prioritise development on the site to improve the user experience and accessibility. 

For example, we identified that some people were having trouble moving through the website because the call-to-action buttons were too small and difficult to click for some users. The communications team addressed this by significantly increasing the clickable area to make the user experience more intuitive and improve accessibility. 

## **Search visibility** 

A key focus for our communications team this year has been to improve the search visibility of the charity’s website. 

Visibility is directly related to search engine rankings. The higher our website ranks on a search engine result page for relevant keywords; the more likely people will see it and click through to our website. 

Page **7** 



The communications team have undertaken a range of tasks this year with the aim to increase the number of people visiting the Glaucoma UK website from both organic search and paid search. 

In 2021, our Digital Communications Officer applied to the Google Ad grant scheme and was successful in securing $10,000 of free advertising a month. Google Ads enable organisations to serve adverts to people who are searching for keywords. For example, if someone searches for ‘driving and glaucoma’, we can serve them an ad to appear at the top of the search results meaning they are more likely to click on it and visit our website. In the previous year, only 656 sessions on our website came from paid searches. Following our successful application for the Google Ad Grant, 10,122 sessions came from paid search results. Of those, over 7,500 were new users who had not visited the site before. 

The team also undertook activities, such as reviewing user experiences on our website and making improvements, creating new high-quality content, and encouraging incoming links, with the aim of improving organic search results. 

During the year, we improved our rankings for six of the 10 keywords related to glaucoma which we monitor and track. These improvements saw our organic search results increase by approximately 39%. 

## **Membership and supporter newsletters** 

Our community of over 4,000 members is at the very heart of our charity and is crucial to our success. 

Members support our work in all sorts of ways, from taking part in surveys, focus groups and consultations, to sharing their personal experiences and supporting our fundraising efforts. The insights we receive from our members keep us connected to the reality of living with glaucoma and help to ensure that our efforts are always focused on the things that matter most. 

Insight magazine, our quarterly membership publication, continues to be a popular and useful resource for our membership. Featuring a range of content including indepth discussions about glaucoma treatments, the latest research, upcoming events and other relevant news, members often get in touch to share their thoughts after each edition. Here are a few highlights from the feedback we received this year: 

**Enjoyed reading latest Insight, very interesting, and some complicated issues clearly explained. Excellent!”** 

**Another really excellent edition of the magazine. Well done to you and the team! I read it from cover to cover – it was my bedtime reading. That in itself is amazing, as generally, with other books, etc – no matter how much I want to stay awake, I fall asleep! […] I really appreciate the “balance” of the information – some very personal, some quite medical and technical, but all very accessible. That really is an achievement.”** 

Page **8** 



Last year we launched Focus - a new digital support newsletter. The number of subscribers to this newsletter has grown to over 1,300. With its mix of news, information and practical advice, Focus is a key tool in our mission to convey our message as cost-effectively as possible to the widest possible audience. 

## **Social media** 

We have maintained a social media presence across Facebook, Twitter and LinkedIn with regular organic content designed to raise awareness of the disease, provide information to live well with glaucoma and advertise the support we can provide. We have also made a conscious effort to feature more stories from the people we support and those who support us with fundraising efforts. 


## **Glaucoma Awareness Week** 

Glaucoma Awareness Week is an annual awareness-raising opportunity coordinated by Glaucoma UK where we encourage people across the UK to talk about glaucoma and find out more about the disease. 

Our 2022 campaign encouraged people to put their sight in the spotlight. With the number of people living with glaucoma in the UK expected to increase by nearly a third between 2020 and 2035, we developed a campaign which urged people to get their eyes tested. 

We created and made public a range of resources for people to use both online and in person to help us spread this message to new audiences including two limited edition printed poster designs, a suite of social media imagery, Zoom/Teams backdrops, and a template press release which people could use to promote their own Glaucoma Awareness Week activities. 

Alongside our organic content, we launched a small set of Facebook Adverts with the aim of increasing awareness beyond our existing audience about the need to have regular eye tests. We also used adverts to encourage sign ups to our communications channels such as our e-newsletter, Focus. 

Our Glaucoma Awareness Week social media adverts reached 52,304 people with a spend of just £240. On average, posts during the campaign week were shared 10 times more than posts in the previous months. 

We also worked also with partner organisations to maximise the reach of our social content during the week, including staging Twitter takeovers on their accounts to help us reach new audiences. 

Page **9** 



A key feature of our campaign was our nationwide radio day which achieved 21 hours of airtime across stations with a collective audience of over 42.5 million listeners. Our interviews featured our Chief Executive and our Head of Support Services talking about the disease, the importance of having regular eye tests and the support available for people living with glaucoma. The average interview lasted over nine minutes which is testament to the skill of our media representatives and interest in the campaign messages. 

A successful PR campaign also secured significant coverage in national and regional publications, including The Optician, Eye News, Optometry Today, Oldham Evening Chronicle, Sunderland Echo and Essex Magazine. 


## **Media activity** 

In addition to our Glaucoma Awareness Week campaign about the importance of eye tests and rising cases of glaucoma in the UK, we secured media coverage for a range of PR initiatives throughout the year, including the launch of our new ‘Easy read: putting in your eye drops’ guide, information about the hereditary nature of the disease and the winner of our Excellence in Glaucoma Care Awards. 

We also provided comment for third-party press activity throughout the year, including the campaign by the Driver and Vehicle Licencing Agency (DVLA) to make motorists aware they must be able to read a number plate from 20 metres away and several awareness campaigns by Specsavers. 

We placed adverts in numerous publications, including the East Kent Hospitals magazine, Vista magazine, The Times, a supplement in The Guardian newspaper, Health and Wellbeing magazine and New Scientist magazine. 

We were also involved in the Ashford International Jubilee Project to celebrate HM Queen Elizabeth II’s 70 years of service. Our commemorative Glaucoma UK artwork was displayed as stained glass along the main walkway of Ashford International train station, one of the largest train stations in Kent, which is used by 3.6 million passengers each year. 

Page **10** 



## **Brand awareness** 

Results of our second annual brand awareness survey showed that awareness levels had increased during the year, with 10% of the survey sample being aware of Glaucoma UK and its work. The survey also provided the following helpful insights: 

- Increasing numbers of people are aware of Glaucoma UK as a result of media coverage (radio / press articles). 

- There is a positive correlation between general glaucoma knowledge and having an eye test in the last two years. 

- There was a high level of ‘spontaneous’ (unprompted) awareness of glaucoma, with over half of the respondents naming it as the first eye condition they could think of. 

- The most commonly held misconceptions about glaucoma are that it can be cured and that it is not possible to drive with the condition. 

The survey will be conducted at the same time next year as part of our drive to capture longer-term data trends. 

## **Sharing personal stories** 

Given the importance of relatability in messaging about glaucoma and its impacts, much of our awareness-raising work during the year focused on the stories of those living with the disease. We added 23 new case studies to our growing resource bank, which now contains the shared experiences of over 60 individuals. Almost half of these new case studies were added to the ‘Your stories’ page of our website and shared on our social media channels. Engagement levels on these posts were high, prompting others to get in touch and share their own perspectives and experiences. Case studies were also featured in Insight magazine and in Focus to help support Glaucoma UK’s fundraising activities and promote our services. 

Case study volunteers supported our work as speakers at digital glaucoma support groups and shared their glaucoma experiences during a virtual parliamentary roundtable event hosted by Lord Low in the early part of the year. They also supported campaign work for Glaucoma Awareness Week and National Eye Health Week. We are hugely grateful for the generosity of those who help us in this way. 

## **Representing the glaucoma community** 

As part of our drive to represent the voice of people living with glaucoma to those providing treatment, designing new models of care and commissioning services, we played an active role in a number of sector collaborations during the year. 

These included the VI (Visual Impairment) Sector Partnership, the National Institute for Health and Care Excellence (NICE) committee for glaucoma guidance and NHS Scotland and the Scottish Government’s launch of www.eyes.scot. 

We also helped our beneficiaries to engage with a range of patient consultations, including the development of a National Low Vision Service for Scotland, new NICE guidance on ab interno canaloplasty, and the National Institute of Health Research (NIHR) priorities for glaucoma research in the period 2022-27. 

Page **11** 



## **Providing Advice and Support** 

The investment in additional capacity for our Development Managers and a Professional Engagement Lead job-share role offered an exciting opportunity for our Support Services team to reflect on existing provision and explore new areas for growth and innovation. In addition to essential groundwork for future strategic development, the team achieved an increase in patient contact throughout the year, with more - and better - opportunities to provide information and advice to those who needed it. 


## **Helpline** 

Our glaucoma helpline, which operates every weekday, remains a cornerstone of our provision. Enquiries increased by 42% on the previous year, with support provided to 2,352 individuals. The most common discussion topic was the impact of glaucoma on driving and DVLA notifications, followed by the various surgery options and questions relating to the use and side effects of eye drops. 

With the ongoing pressure on healthcare systems impacting on the frequency and duration of eye health appointments, the ability to access practical advice and emotional support is invaluable to many of the individuals who contact us. We recognise the path from diagnosis to living well with glaucoma is not a linear one for most people and our helpline continues to play a key role in helping people find the answers and reassurance they need, at every stage of their diagnosis and treatment. The following feedback received during the year helps to highlight the crucial role played by our Helpline Advisers: 

**Thanks a lot for your prompt responses... This session really soothed my mind a lot.”** 

**I would like to thank you very much for being there when needed.”** 

- **I am sending the biggest cyber hug ever. I have tears running down my face in appreciation of your response.”** 

**I can't begin to thank you enough for your email - it is so understandable and has taken away much of the fear and concern that I've carried around with me since seeing the optician.”** 

Page **12** 




## **HealthUnlocked** 

Our online glaucoma community on HealthUnlocked 

- (www.healthunlocked.com/glaucoma uk) has continued to grow during the year, with membership reaching 1,169 - a very encouraging increase of 81% on the previous year. A total of 5,737 connections were made between forum users, sharing insights, experiences and providing peer-to-peer support. The exchanges on the forum are overseen by our Helpline Advisers, who help to provide additional advice and information where it is needed. Plans to increase capacity within our Support Services team in 2023 will enable us to engage even more actively with the HealthUnlocked community, including better signposting for users to other relevant Glaucoma UK services. 

## **Digital glaucoma support groups** 

Following their successful introduction during the COVID-19 pandemic, the delivery of digital glaucoma support groups continued in 2021/22. We saw a 20% increase in registrations on the previous year and over 700 attendees joining sessions on a wide range of subjects, including: 

- Glaucoma-friendly yoga 

- Changing glaucoma care – virtual clinics and community monitoring 

- Glaucoma and genetics 

- Glaucoma in focus – normal tension glaucoma 

- Minimally invasive glaucoma surgeries 

- All about eye drops 

- Glaucoma and driving 

- Who can help if I’m losing my sight to glaucoma? 

Page **13** 



In addition to these topics, we achieved our objective for the year to run more sessions involving patient speakers describing their experiences and taking questions from the audience. Feedback from participants has revealed that our digital glaucoma support groups are a valuable source of information, comfort and confidence for attendees: 

**Many, many thanks to you, Glaucoma UK for your brilliant webinar! It answered many questions for me and joined up so many previously disconnected bits of information. I feel so much happier, more confident and in control of my condition now that I will certainly be less apprehensive when I go for my appointments at the hospital.”** 

**I would like to say thank you for the webinar yesterday, during this dreadful pandemic isolated and with difficulty accessing medical attention the meeting yesterday gave me confidence to use pain relief medication.”** 

**I feel a lot more positive so a big thank you.”** 

**As usual a most enjoyable zoom with pharmacists and reassuring information.”** 

**I have been suffering from glaucoma for 10+ years and this is the most useful thing I have ever heard within this time. To hear it from someone else who can share their own experiences has been so much more beneficial than the NHS staff who have not been able to put it into words that mean much to me.”** 

**Wonderful webinar, very informative and delivered very well. I have learnt so much which will allow me to support clients moving forward.”** 

**That was a fact-finding fabulous zoom, I learnt so much as well.”** 

A staggering 99% of attendees would recommend our digital glaucoma support groups to other people affected by glaucoma, and around nine out of 10 attendees feel the sessions are informative, clear and easy to understand. 

## **Face-to-face support** 

Although digital interventions remain an excellent way to expand our reach and engage with larger numbers of beneficiaries in an efficient and cost-effective way, we remain committed to providing face-to-face support to those who need it. The threat of a new wave of COVID-19 infections dogged activity for the first half of the year, but it was rewarding to re-establish our community-based glaucoma support groups and other in-person events in the spring of 2022. 

Page **14** 



Considerable work was undertaken in the year to explore new models for increasing contact with our beneficiaries and to improve the management and evaluation of our regional engagement in the future. Over 10 months, our Development Managers consulted with people living with glaucoma, key professionals and staff to help inform a review of support group delivery and feed into a new strategy for optimising the education and empowerment of people with glaucoma in a rapidly changing healthcare environment. 

Findings of the consultation revealed that bringing people together, facilitating relationships and creating a sense of ‘togetherness’ were integral to the delivery of our community-based support. Support groups may serve multiple functions including education, emotional support and social interaction. To maximise the reach of support groups and ensure that the benefits are experienced by a larger number of people, a new framework has been developed to facilitate delivery by health care professionals, with guidance, resources, oversight and ongoing support provided by the Glaucoma UK team. The new framework will be piloted in the coming year. 

In broadening the scope of our face-to-face support, we remain focused on the importance of identifying and engaging those populations most at risk of glaucoma sight loss. Work in this area during the year has highlighted the need to leverage the right community, corporate and charity partnerships to increase our reach, as well as the importance of establishing effective impact measuring tools. These priorities will continue to underpin our strategic development in this area in the coming year. 


## **Information booklets** 

Our suite of information materials remains an important resource for people living with glaucoma and those providing their care. Over 90,000 information guides were ordered during the year and 6,348 booklets were downloaded from our website. A new easy read guide - ‘Putting in your eye drops’ - was added to the portfolio in early 2022 and has become one of our most popular resources. 

Page **15** 



Plans to re-write and relaunch our full set of publications during the year were delayed by staff capacity issues. Following a resource review, a new health information manager role is to be introduced to take the project forward in 2023. 


## **Professional engagement** 

Working in partnership with professionals to improve outcomes for people with glaucoma is a key strand of our charitable mission. The support we provide takes a range of forms, including the provision of information resources, recruiting patients for clinical trials, staff participation in research steering committees and free professional membership of Glaucoma UK. 

Devolved health and social care across the four nations creates not just political differences but also variations in resource and methodology. The focus of our professional engagement work is to encourage the sharing of best practice and to spotlight glaucoma in a crowded health field. A key task is to prioritise the patient perspective and identify the areas where behavioural change for those providing glaucoma care can have the greatest impact. 

Following a review and scoping exercise by our new professional engagement leads, an ambitious new strategy has been developed to more effectively address the communication, training and support needs of different glaucoma professionals. This approach recognises the significant overlap between different professional groups, while also acknowledging the development priorities for individual practitioners at different stages of the glaucoma treatment process. Although specialists may have occasional involvement, generalists may have more frequent or lengthier interventions. Carers, families and social care may ultimately have the greatest influence over whether someone feels able to effectively manage their own treatment and so the new strategy reaches beyond those in clinical roles. 

Page **16** 



The scope of Glaucoma UK’s training programme (which was originally just for eye care liaison officers) became broader during the year, with training now available for rehabilitation officers, optometry units, sight support staff and carers. Work to deliver a new accredited training programme for optometrists is ongoing and we are currently reviewing how best to utilise the programme funding in light of changes in glaucoma care and optometry training requirements since the inception of the project. 

The development of new ‘eye drop support boxes’ was a major focus for 2021/22, with boxes now being dispatched to NHS and not-for-profit organisations across the UK. These boxes are a vital tool for eye care professionals to help people manage their eye drop regime and live well with glaucoma. They also provide an invaluable Glaucoma UK presence out in the community. Availability of the boxes will be expanded in the future to include sale to commercial optometrists and pharmacies. 

A major focus of our professional engagement activity is our work with the UK and Éire Glaucoma Society (UKEGS), which officially merged with Glaucoma UK in 2019. UKEGS is a national scientific society which aims to bring glaucoma specialists together in order to stimulate research and protect the interests of people living with - or at risk of developing - the disease. With a current membership of approximately 500, the Society’s annual conference is an important vehicle for networking and knowledge exchange. The ongoing threat of COVID-19 led to the postponement of the conference during the year, but the rescheduled event for October 2022 – focusing on ‘Safety and success in glaucoma care’ – attracted 260 delegates and speakers to an informative and thought-provoking two-day lecture programme. 

## **Volunteering** 

We continued to recruit volunteers to our ‘buddy’ scheme during the year and now have a bank of 39 individuals who can be called upon to share their experiences of various clinical procedures with others who may be facing glaucoma surgery. The reassurance and emotional support provided by our buddies is invaluable in helping people to make informed choices about their glaucoma treatment and we are most grateful to them for their commitment to our charity. In preparation for growing and broadening the scope of our buddy scheme, work was undertaken during the year to review all procedures relating to volunteer risk management, training provision, data management and safeguarding. We hope to widen the scope of our buddy scheme to include recruitment of buddies with sight loss, those who are newly diagnosed and those with congenital glaucoma. 

Volunteers also play a vital role in providing insight and feedback to help inform our work. We are grateful to the members of our Readers Panel and Consultation Panel who give their time to review and comment upon research proposals, NICE guidance and the content of our information booklets. 

Page **17** 



## **Funding Research** 

The delivery of an annual research programme is a key charitable objective for Glaucoma UK and is an essential part of our mission to improve the detection, care and treatment of glaucoma. Following the disruption of the pandemic, it was encouraging to see all delayed research studies being resumed during the last year. 


## **Completed projects** 

The findings of a Glaucoma UK funded 2015 RCOphth Award Project to investigate the quality of life at different stages following glaucoma surgery were reported in July 2022. Led by Professor Anthony King of Nottingham University Hospital, the project measured the experiences of 154 patients following a trabeculectomy operation. The study concluded that health-related quality of life is affected negatively in the immediate post-operative period but returns to normal by the third month after surgery. Restrictions in physical and social functioning as well as physical and emotional role limitations were the factors that contributed most to the fall in healthrelated quality of life. There were no significant variations in quality of life for general health, mental health, pain or vitality. The study has provided important information that may be used to reassure and prepare future trabeculectomy patients. 

We were also presented with the findings of the Glaucoma UK funded UKEGS Award study from 2015, exploring the application of virtual reality (VR) technologies for conducting perimetry tests. In her research, Dr Jenny Bosten of the University of Sussex, set out to demonstrate the potential advantages of VR for more frequent monitoring, ease of use in the home and increased accessibility for patients with impaired mobility. The study found that there was no substantial difference in reliability between the new test using a head mounted display and the standard clinical assessments for patients with glaucoma. 

Next steps include seeking further funding to refine the test to make it more accessible for those living with dementia and to undertake trials in international settings where standard clinical equipment is unavailable. 

Page **18** 



## **New awards** 

The following new grants were awarded in the year: 

- £98,000 - PhD Studentship, Dr Ben Mead, Cardiff University Hospital ‘Exosomes as a therapy for glaucoma’ starting October 2022. 

- £45,271 - Open Call Award, Dr Andrew Tatham, Princess Alexandra Hospital, Edinburgh, ‘Evaluation of a new low-cost applanation tonometer (Newton)’ starting October 2022. 

- £99,910 - Royal College of Ophthalmologists Award, Professor Colin Willoughby, Ulster University, ‘Development of a disease modifying biologic therapy’ starting April 2023. 

- £57,300 - Royal College of Ophthalmologists Award, Professor Anthony King, Nottingham University Hospital, ‘Translating the complications of glaucoma surgery into meaningful everyday consequences for glaucoma patients’ starting November 2022. 

## **Chair of Ophthalmology** 

A significant element of the charity’s research strategy is the ongoing financial support of the Glaucoma UK Chair of Ophthalmology for Glaucoma and Allied Studies at UCL. Ranked in the top ten of the ‘Ophthalmologist Power List 2020’, Professor David (Ted) Garway-Heath is a global leader in ophthalmology research. His achievements for the year include: 

- The award of a major new grant of £1.9 million by the NIHR for a clinical trial to test the effectiveness of vitamin B3 as a treatment for glaucoma, which may actually help to improve vision, rather than just prevent deterioration. The study, for which Professor Garway-Heath is chief investigator, will start in January 2023 and patients will be recruited from seven centres across the UK. 

- The delivery of seven ongoing grant projects, including, “Identifying the genetic basis for heritable normal tension glaucoma, with a focus on mitochondrial function” and “The association between mitochondrial function and glaucoma – identifying susceptible patients”. 

- Sixteen peer-reviewed scientific publications, including British Medical Journal and Journal of the American Medical Association. 

- Strategic input to the planning, structure and programme of the 15th biennial Congress of the European Glaucoma Society (EGS). 

- Mentor to an NIHR lecturer at Moorfields Eye Hospital/UCL Institute of Ophthalmology as part of the NIHR Clinical Lectureship Post-Doctoral Award. 

- Primary supervision of three PhD students and mentor to three research fellows from Italy, Spain and Japan. 

- EGS Ambassador to the American Glaucoma Society, with the aim of strengthening the links and collaborations between the two societies in terms of the education and training of ophthalmologists. 

- Delivery of 19 national and international lectures, including three keynote speeches. 

Page **19** 




## **Fundraising Review** 

Voluntary income during the year consisted of subscriptions for our membership scheme, one-off gifts, regular giving, in memoriam donations, legacies, corporate support, supporter challenge events, Christmas card sales and a weekly lottery. 

Total fundraised income was £1,816,137, with legacies accounting for over 80% of the total income. Legacy gifts remain a lifeline for the charity and the work we do. We are indebted to all those, past and present, who have remembered Glaucoma UK in their will. 

General donations and subscriptions fell by £12,995 on the previous year (2022: £178,593 – 2021: £191,548). Corporate donations were also down (2022: £1,841 – 2021: £27,000), reflecting the uncertainty of the wider economic climate and also the requirement to focus fundraising resource on higher than usual levels of legacy administration during the year. 

In its second year of operation, our weekly lottery showed a pleasing level of growth, generating income of £16,034 (2021: £6,731) with associated costs of £7,167 (2021: £3,009) consisting of prizes and scheme fees. As part of the one-year anniversary celebration for the Glaucoma UK Lottery, we were able to share the story of a £1,000 New Year’s Eve winner in Insight magazine and on social media, encouraging 39 new players to sign up. 

We were delighted with the response to our Glaucoma Awareness Week appeal in June, which focused on the personal story of someone living with glaucoma and the importance of the support they received from Glaucoma UK. Over 130 individuals were moved by the appeal, making donations totalling £14,856. 

We were grateful to our supporter Keith Barton, who cycled from London to Paris to raise funds for the charity. A consultant ophthalmologist and former Glaucoma UK Chair, Keith has been a career-long advocate of the charity and its work. Achieving the feat in less than 24 hours, Keith raised a remarkable £9,580. 

Page **20** 



We would also like to take this opportunity to thank the following organisations for their support during the year: 

- Harry and Gertrude Landy Charitable Trust 

- The Dandy Charitable Trust 

- Wyseliot Rose Charitable Trust 

- The Emily Weircroft Charitable Trust 

- The Wyndham Charitable Trust 

- Spire Little Aston Hospital 

- Specsavers UK 

- Thea pharmaceuticals 

All fundraising was carried out by Glaucoma UK staff and no external fundraisers were used. We employed one fundraiser during the year (Head of Fundraising) who is an Institute of Fundraising member. A new Legacy and Supporter Relationship Officer joined the team in the autumn of 2022. This will increase capacity and allow the Head of Fundraising to give more time to the diversification of income to reduce the current reliance on legacy gifts. 

Glaucoma UK is registered with the Fundraising Regulator and follows the Code of Fundraising Practice. We comply with the key principles embodied in the Code and are committed to the Fundraising Promise. Our website carries our complaints policy for the public and explains clearly how an individual may raise a concern. We received no complaints from August 2021 - July 2022. We are also registered with the Fundraising Preference Service so that individuals can opt out from receiving fundraising communications, should they wish. We received no such requests during the year. 

At Glaucoma UK, we strive to treat all donors and the public fairly, showing sensitivity and adapting our approach, depending on supporters’ needs. In line with Institute of Fundraising guidance, we ensure that all reasonable steps are taken to protect vulnerable adults and take care not to use any imagery or language that could cause distress or anxiety. 

Glaucoma UK monitors any third parties working with us to help raise funds, ensuring that they adhere to the Code of Fundraising Practice and comply fully on both a legal and ethical level with the objectives of Glaucoma UK. We ensure that third parties are operating to the highest possible standards of respect for the personal data and wishes of our supporters and prospective supporters. 

Fundraising activity is closely monitored using a range of financial and non-financial data, including return on investment, comparison with sector benchmarks, and against the standards set out in our Ethical Fundraising Policy and Supporter Promise. One of our Board members is a Fundraising Trustee Advocate, to ensure oversight of our fundraising activity at the highest level. 

Page **21** 




## **Looking Forward** 

The theme of last year’s annual report was ‘expansion’ and - despite the disruptions caused by a change of leadership and the unsettled operating environment – we achieved success across a number of areas. We increased the capacity of our Support Services team, helped more people on our helpline, welcomed more people to our digital glaucoma support groups, recorded more visits to our website and helped to inform more people through wider circulation of our ‘Insight’ and ‘Focus’ publications. 

We know, though, that the number of people living with glaucoma in the UK is continuing to rise and the devastating legacy of the pandemic continues to be felt within the eye care system. So, there is no room for complacency. To further maximise our impact in the most cost-effective way, our key priority for the coming year is to finalise and implement a new organisational strategy that moves us as quickly as possible to the achievement of our strategic vision – an end to preventable glaucoma sight-loss. 

A new strategy map has been produced, setting out our vision, mission and strategic objectives, along with the enablers required to achieve them. This will be supported by a Theory of Change framework, to help to convert the strategic concepts into measurable work on the ground. 

By supporting the identification, capture and dissemination of impact data, the Theory of Change process will help us to more readily demonstrate Glaucoma UK’s value to beneficiaries, members, supporters and the wider professional community. Most importantly, it will ensure a shared understanding between all internal and external stakeholders about where and how the work of Glaucoma UK can make the greatest difference. 

Page **22** 




## **Our Finances** 

## **Financial Review** 

The financial year 2021/22 proved to be unpredictable and challenging in a number of ways. Although confidence grew during the course of the year with regards to the pandemic, activity levels continued to be constrained in the early months by the threat of a new wave of COVID-19. Just as tentative signs of social and economic recovery started to emerge in early 2022, a further period of economic turbulence began, prompted by the war in Ukraine and the UK’s subsequent cost-of-living crisis. The charity ended the financial year with net income of £362,717, but investment assets were affected, resulting in a net movement of funds of -£132,888 due to unrealised investment losses of £495,605. 

## **Incoming resources** 

Total incoming resources for the year were £1,841,823, representing an increase of £45,997 on the previous year (2021: £1,795,826). The impact of the wider economy was felt in some areas, particularly donations, subscriptions and corporate support, which collectively showed a £39,973 reduction on 2021 levels. Legacy income remained stable at £1,490,953 (2021: £1,412,867). We recognise that this is an uncertain and unpredictable income stream and continue to be extremely grateful for the generosity of those who remember Glaucoma UK in their wills. With no statutory funding received by the charity (with the exception of furlough scheme payments during the pandemic), such significant voluntary gifts help to give vital stability to our work. Legacies enable us to commit to the longer-term plans that are essential in achieving our ambitious vision to end preventable glaucoma sight-loss. 

Income from charitable activities was £25,686, down by £40,217 on the previous year (2021: £65,903). This was mainly the result of postponing the annual UKEGS Conference until October 2022 in response to ongoing social distancing concerns in the first half of the financial year. 

Page **23** 



At £14,471, total income from grants received during the year was down by £32,923 (2021: £47,394). The Government’s Job Retention Furlough Scheme came to an end in September 2021, with only £62 received during the year, compared to £19,368 during 2021. Income in the previous year was also bolstered by a National Lottery grant of £16,546. The project, which enabled us to research potential new models of digital support to help people stay connected during lockdown, was completed under budget and a repayment of £1,142 was made to the National Lottery Community Fund in 2022. 

## **Resources expended** 

Total expenditure in the year rose by 41% to £1,479,106 (2021: £1,042,652). The principal area of growth was research, with a £254,512 increase in grant awards (2022: £364,945 - 2021: £110,443). 

Staff costs also increased to £665,097 (2021: £582,119) following the investment in additional support services and data insights personnel. Total staff numbers at the year-end were 23 (17.3 full-time equivalent) compared to 20 (16.28 full-time equivalent) at the end of 2021. This continues a sustained period of investment in human resource, with staff numbers having grown from 12.7 full-time equivalent in 2018 – a key factor in the ongoing growth in range and quality of services we provide. 

The requirement to contract an interim CEO for the period January to April 2022, along with professional support for data protection, legal advice, strategy development and senior management training, led to an increase in finance and professional fees of £101,780 on the previous year (2022: £177,436 – 2021: £75,656). 

At £20,066, fundraising expenditure was down by £13,519 on 2021 levels. This reflects a reduction in fundraising events due the ongoing COVID-19 uncertainty in the early part of the year and the requirement to allocate more time and resource to legacy administration. 

Glaucoma UK’s restricted funds totalled £1,594,377 at the year-end. The majority of this figure (£1,494,729) represents the Chair Fund, which will support the Chair of Ophthalmology for Glaucoma and Allied Studies until his eight-year term comes to an end in 2026. Of the remainder, £48,228 is restricted to the work of UKEGS. 

## **Reserves Policy** 

The policy of the trustees is to maintain at least the minimum level of cash reserves to meet the day-to-day needs of the charity, to provide secure, sustainable support for our beneficiaries and to ensure we can commit to ambitious long-term plans to end glaucoma sight loss. 

Page **24** 



The trustees recognise the risk to income posed by the reliance on legacy gifts and factors outside the organisation’s control, such as pandemic and a backdrop of ongoing economic uncertainty. Having considered these factors, the Board of Trustees agreed to maintain a general reserve of 18 months’ operating costs during the year. This will be reviewed during 2022/23 to ensure that the holding remains appropriate, given the emergence from COVID-19, while remaining mindful of the ongoing threat of recession and the associated risks of income and investment volatility. General funds totalled £2,081,888 (2021: £1,727,616) at the year-end, against an operating cost requirement of £2,128,664. 

Designated funds totalled £6,564,794 (2021: £6,210,522), of which £4,000,000 was allocated to the delivery of a new research strategy, currently in development. An equipment and infrastructure fund of £460,000 was designated for the redevelopment of our office accommodation, to consolidate operations post COVID19 and reduce overheads in the longer term. 

Restricted funds of £1,594,377 (2021: £2,082,540) included £1,494,729 committed to funding the remaining 3-year term of the Chair of Ophthalmology for Glaucoma and Allied Studies at UCL. A total of £48,228 was restricted to the work of the UK and Eire Glaucoma Society (UKEGS), including the annual conference and research award. The remaining £51,420 represented funds donated or awarded for activity in specific areas and will be allocated as appropriate opportunities arise. 

## **Going Concern** 

In assessing the charity's status as a going concern, the trustees have considered a range of information in relation to the financial year ahead, including the current status of the pandemic, the impact of the war in Ukraine on the UK economy, the charity’s cash resources and known liabilities. Although the macro-economic situation is volatile and deemed to pose some risk to fundraised income, corporate support and staff costs, the trustees consider the charity to have adequate resources to continue operating an effective service for at least 12 months and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis. 

Page **25** 



## **Investment Policy** 

Our Investment Policy is: 

- To maximise total return subject to an agreed level of risk. 

- To ensure that the charity’s assets are invested widely and diversified by asset class and by security. 

- To avoid direct investment in any companies manufacturing tobacco or tobacco products. 

- To avoid investment in any companies that derive more than 10% of their revenues from the manufacture of alcoholic beverages, armaments, gambling, high interest rate lending or pornography. 

The charity’s assets are invested in the Rathbone Core Investment Fund for Charities, with management delegated to Rathbone Investment Management Ltd. The move from a mixed portfolio to a single, pooled fund in February 2021 enabled the charity to take advantage of lower management fees, ease of administration and a UK registered fund, with all income coming from the UK. 

Responsibility for monitoring the performance of the investment portfolio is delegated to the Finance and Governance Committee and performance benchmarks are reviewed with the fund managers on an annual basis. 

Investment assets showed a net loss of £18,376 at 31 July 2022. Although £492,201 was invested during the year, the total fund value fell by £495,605 as a result of ongoing market instability and the threat of recession. The trustees are aware that the economic uncertainty in relation to inflation and growth will continue for the foreseeable future and this has been taken into account in a review of the Investment Policy for the year 2022/23. 

Page **26** 



## **Governance and Leadership** 

## **Trustees, Advisors and Staff** 

The trustees (who are also directors under company law) are: 

|**Professor Philip Bloom**|Chair(to 11.03.22)|
|---|---|
|**Professor Anthony King**|Chair (from 11.03.22)|
||Chair,Clinical AdvisoryPanel(to 11.03.22)|
|**David Sanders**|Hon Treasurer(to 22.06.22)|
|**Prabhakar Sundaresan**|Hon Treasurer(from 22.06.22)|
|**Stephen Epstein**|Vice Chair|
|**Dr Winifred Nolan**|Chair,Clinical AdvisoryPanel(from 11.03.22)|
|**Teresa Borsuk**||
|**Dr Roxanne Crosby-Nwaobi**||
|**Dr Susan Blakeney**||
|**Julian Exeter**||
|**Yolanda Laybourne**||
|**Ray Spendiff**||
|**Dr Cecilia Fenerty**|(from 11.03.22)|
|**Dr Roshini Saunders**|(from 11.03.22)|
|**Christopher Hunton**|(co-opted from 11.02.22)|
|**Chief Executive and**|Karen Osborn (to 13.01.22)|
|**Company Secretary**|Claire Cardy (from 13.01.22 to 27.04.22)|
||Joanne Creighton (from 27.04.22)|
|**Company Number**|1293286|
|**Charity Number**|274681|
|**OSCR Number**|SC041550|
|**Registered office &**|Woodcote House, 15 Highpoint Business|
|**operational address**|Village, Henwood, Ashford, Kent, TN24 8DH|
||www.glaucoma.uk|
|**Bankers**|Barclays Bank plc, 1 Churchill Place, London,|
||E14 5HP|
||CAF Bank Ltd, 25 Kings Hill Avenue, Kings Hill,|
||Kent, ME19 4JQ|
||HSBC Bank plc, Camberwell Green, 23|
||Denmark Hill, London, SE5 8RP|
|**Auditors**|Xeinadin Audit Limited, 1 City Road East,|
||Manchester, M15 4PN|
|**Investment Managers**|Rathbone Investment Management Ltd,|
||8 FinsburyCircus,London,EC2M 7AZ|



Page **27** 



## **Structure and Management** 

Glaucoma UK is the operating name of the International Glaucoma Association Ltd, which was incorporated on 15 July 1976 and registered as a charity on 20 December 1977. As Glaucoma UK is both a charity and a company limited by guarantee, all board members are directors for the purposes of company law and trustees for the purposes of charity law. 

The objects of the charity are defined by its Articles of Association (last updated in 2015), which also set out trustees’ powers and the permitted activities of the charity. 

Following a review of the Articles of Association in 2021, with help from Russell Cooke solicitors, it was felt that moving from a membership model to an association model may be more appropriate for the charity. All voting members were invited to give their views on the proposal, with 59% of respondents supporting the change, 36% against and 5% undecided. In September 2021, the charity communicated individually with all those who were against the change, answering their questions and responding to their comments and suggestions. Dialogue continued during the autumn, and the matter was debated at the Board of Trustees’ meeting in September 2021. As the response rate to the initial consultation was very low with only 56 replies, trustees were keen to ensure that everyone involved in the charity had the opportunity to have their say. The decision was therefore taken to defer plans to put the proposals to the AGM in March 2022 to allow for further consultation and involvement of the new Chief Executive Officer. Any changes to the Articles of Association will now be presented for a vote at the AGM in March 2023. 

## **The Board and Committees** 

The Board comprises a maximum of 15 trustees, of whom up to 12 are elected by the members and a further three may be co-opted. The current Board comprises people living with glaucoma, those with close family connections with the condition and others with backgrounds in ophthalmology, nursing, optometry, finance and business. Existing trustees retire after serving a three-year term but are eligible for re-election to a maximum of twelve years’ service. There is one sub-committee: the Finance and Governance Committee, which has delegated responsibility to oversee finance, investments, risk management and policy. Consisting of six trustees, the committee meets quarterly in advance of each Board meeting and on an ad-hoc basis, should the need arise. The charity also has a Clinical Advisory Panel (CAP) to advise on clinical matters. The chair of the CAP oversees the award of research grants. 

The Board returned to face-to-face meetings in 2022, with the option to join virtually for those unable to attend in person. This hybrid approach has been successful in reducing cost, lowering carbon footprint and ensuring that individuals can make a positive contribution, regardless of time or geographical constraints. 

Page **28** 



## **Trustee recruitment and training** 

When appointing new Board members, trustees have regard to any skills or knowledge gaps and seek candidates to meet those needs. Due consideration is also given to diversity and the need to ensure that the Board appropriately represents the communities served by the charity. New trustees are sought using existing networks, advertising or professional recruitment agencies, as required. Candidates are interviewed by a sub-committee of trustees, followed by a meeting with the Chair and an invitation to meet the full Board at a Board meeting. 

A Trustee Handbook sets out trustee roles and responsibilities. A personalised induction is provided for all new trustees, including a charity overview and briefings on finance, fundraising, support, services and communication. Direction is also provided on the Charity Commission Guidance, ‘The Essential Trustee’. Ongoing training is provided as required, including attendance at external courses or participation in internal workshops and briefings. 

## **Conflict of interest** 

Charity Commission approval was sought and received during the year in relation to a research grant award to Nottingham University Hospitals Trust for which Glaucoma UK Chair – Professor Anthony King – will be lead researcher. The Commission were content that the conflict of interest had been managed appropriately and that the trustees had acted in accordance with Glaucoma UK’s Memorandum and Articles of Association and Charity Commission guidelines when sanctioning the award. 

## **Operating responsibility** 

Day to day responsibility for delivering services and achieving strategic and financial aims within organisational policies and the law is delegated to the Chief Executive Officer, supported by the Senior Management Team. 

## **Statement of Public Benefit** 

Glaucoma UK exists to raise awareness of the risks of glaucoma, support people to live well with the condition and fund research into the causes, prevention and treatment of the disease. When reviewing the charity’s objectives and planning future activities, the trustees refer to Charity Commission guidance on public benefit and can confirm that all Glaucoma UK’s activities are undertaken to further our charitable purposes for public benefit, in accordance with Section 17 of the Charities Act 2011. 

## **Related Parties and Connected Charities** 

Glaucoma UK acted as an agent for the unincorporated organisation the United Kingdom Paediatric Glaucoma Society (UKPGS) during the year, providing infrastructure and administrative support. UKPGS exists to promote the exchange of knowledge between glaucoma specialists, stimulate research, establish a scientific community and promote interest in glaucoma as an ophthalmological sub-specialty. One trustee of Glaucoma UK also sits on the trustee board of UKPGS. 

Page **29** 



## **Risk Management and Internal Control** 

Overall responsibility for the charity’s risk management lies with the Board of Trustees, with formal assessment and review delegated to the Finance and Governance Committee. A risk register is submitted by the Chief Executive to the Finance and Governance Committee on a quarterly basis which identifies current and new risks, rates each in terms of likelihood and probability and identifies appropriate controls and mitigations. The trustees have assessed the major risks to which Glaucoma UK is exposed as follows: 

## **Lack of income diversity and heavy reliance on legacy gifts** 

With legacy gifts representing 81% of our income in the year 2021/22, the need to diversify funding sources is a key priority for the charity. In mitigation, the following measures are in place: 

- Income position monitored via quarterly management accounts. 

- Cash flow forecasts and detailed reports on the legacy gift pipeline. 

- Reserves holding and investment portfolio with diversified risk to cover medium and longer-term income shortfalls. 

- Staff capacity increased in the Fundraising department in October 2022 to create additional resource for income diversification. 

- New strategy in development to identify opportunities for greater corporate sponsorship and funding from charitable trusts and foundations in support of Glaucoma UK’s work with communities at highest risk of glaucoma. 

## **Investment failure** 

All investments are at risk of sustained and long-term fall in value of funds held in stock markets. The risk to Glaucoma UK’s investment holdings has been mitigated in the following ways: 

- Investments managed by Rathbones who monitor performance and take corrective action as required. 

- Access to live online investment reports. 

- Quarterly reporting to Finance and Governance Committee and annual meeting with investment managers. 

- Investment Policy reviewed annually. 

- Minimum of three months’ operating costs held in cash account. 

Page **30** 



## **Compromised IT systems and cyber security failure** 

In response to increasing levels of cybercrime in the UK and a tightly regulated data protection environment, the following mitigations are in place: 

- Retained professional support for staff training and regular system security monitoring. 

- Biannual cyber security training mandatory for all staff. 

- Cyber Essentials Plus principles followed in all IT management activity. 

- Daily offsite backup & office-hours support contract in place. 

- Appropriate policies in place (Information Governance, ICT, Data Protection) and subject to annual review. 

- Cyber insurance in place, with support for post-incident management. 

## **Remuneration Policy** 

The trustees consider the Board of Trustees and the Chief Executive Officer as comprising the key management personnel, in charge of directing, controlling and operating the charity on a day-to-day basis. All trustees give of their time freely and no trustee remuneration was paid in the year. Trustees are required to disclose all relevant interests and withdraw from decisions where a conflict of interest arises. 

The pay of the charity’s Chief Executive is reviewed annually by the Board Chair and Finance and Governance Committee. The Chief Executive reviews all other staff salaries annually and makes recommendations to the Board as part of the annual budget setting process. 

When setting salaries, trustees are guided by a remuneration policy that considers factors such as pay comparability (benchmarked within our own sector but also referencing public and private sector pay increase estimates), affordability, sustainability, and appropriateness. Glaucoma UK aims to set salaries at a level where the ratio between the highest and lowest full-time equivalent is below 4.5:1 and the ratio between the highest and median (midpoint) salary is less than 3.5:1. As at 1 August 2022 these ratios were 3.7:1 and 2.3:1 respectively. 

Page **31** 



## **Statement of Trustee Responsibilities** 

The trustees are responsible for preparing the Trustees' Annual Report including the strategic report and financial statements in accordance with applicable law and United Kingdom accounting standards (UK generally accepted accounting practice). 

Company law requires the trustees to prepare financial statements which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charities SORP; 

- make judgments and estimates that are reasonable and prudent; 

- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business. 

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time, the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 

In so far as the trustees are aware: 

- there is no relevant audit information of which the charitable company's auditor is unaware; and 

- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information. 

The Trustees’ Annual Report is approved by order of the Board of Trustees, and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as directors, in their meeting on 23 November 2022, and signed on its behalf by 

## **Professor Anthony King (Chair)** 

Page **32** 



## **Independent Auditors’ Report** 

We have audited the financial statements of The International Glaucoma Association Limited for the year ended 31 July 2022 on page 36 to 52. The financial reporting framework that has been applied in their preparation is applicable law and FRS 102 (effective January 2015), as well as the Statement of Recommended Practice for Charities (effective January 2015). 

This report is made solely to The International Glaucoma Association Limited's members and Board of Trustees, as a body, in accordance with Section 144 of the Charities Act 2011, and regulations made under Section 154 of that Act, as well as Section 44 (1) ( c ) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Council of Management those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed. 

## **Respective responsibilities of trustees and auditors** 

As explained more fully in the Trustees Responsibilities set out on page 32, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. 

We have been appointed as auditors under Section 44 (1) ( c ) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 and report in accordance with regulations made under those Acts. 

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors. 

## **Scope of the audit of the financial statements** 

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. 

This includes an assessment of whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. 

In addition, we read all the financial and non-financial information in the Trustee’s Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently 

Page **33** 



materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. 

If we become aware of any apparent material misstatements or inconsistencies, we consider the implications for our report. 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities. The extent to which our procedures can detect irregularities, including fraud, is detailed below: 

- Gaining a full and extensive knowledge of the entity, environment and the regulatory framework to which it must abide by. 

- Evaluating and assessing the extent to which the entity’s internal systems are adhering to these as well as gaining a full and comprehensive understanding of the entity’s activities and effectiveness of its control environment (including those in place to identify and prevent fraud). 

We achieved this by carrying out the following: 

- Enquiry of the detailed communication with management and those charged with governance 

- Reviewing internal systems and controls 

- Reviewing financial statement disclosures and compliance with applicable laws and regulations. 

## **Opinion on financial statements** 

In auditing the financial statements, we have concluded that the trustees/directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the entity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorized for issue. 

Our responsibilities and the responsibilities of the trustees/directors with respect to going concern are described in the relevant sections of this report. 

In our opinion, the financial statements: 

- give a true and fair view of the state of the charitable company's affairs as at 31 July 2022 and of its incoming resources and application of resources, including its result, for the year then ended; 

- have been properly prepared in accordance with the Financial Reporting Standards 102 (effective January 2015) 

- have been prepared in accordance with the requirements of the Companies Act 2006, and Section 44 (1) ( c ) of the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 

Page **34** 



## **Matters on which we are required to report by exception** 

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion: 

- the information given in the Report of the Board of Trustees is inconsistent in any material respect with the financial statements; or 

- the charitable company has not kept adequate accounting records; or 

- the financial statements are not in agreement with the accounting records and returns; or 

- we have not received all the information and explanations we require for our audit. 

## **Nicholas Hume** 

For and on behalf of Xeinadin Audit Limited, 

Chartered Accountants and Registered Auditors 

- 1 City Road East, Manchester, M15 4PN 

Eligible to act as an auditor in terms of Section 1212 of the Companies Act 

## **30 November 2022** 

Page **35** 



The International Glaucoma Association operating as **Glaucoma UK** 

## Financial Statements **for the year ending 31 July 2022** 






**2021/22** 



## **Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

**Statement of financial activities** _(incorporating an income and expenditure account)_ **For the year ended 31 July 2022** 


**----- Start of picture text -----**<br>
2022 2021<br>Restricted Unrestricted Total Total<br>Note £ £ £ £<br>Income<br>Donations, Legacies and Subscriptions 2 11,165 1,660,222 1,671,388 1,631,415<br>Investment income 3 33,072 111,678 144,749 98,507<br> Charitable activities<br>Glaucoma aids and equipment sales 4 - 4,654 4,654 4,213<br>UKEGS (UK & EIRE Glaucoma Society) 4 - - - 9,703<br>Other income 4 - 6,561 6,561 4,594<br>Grants  4 & 5 14,409 62 14,471 47,394<br>Total income 58,646 1,783,176 1,841,823 1,795,826<br>Expenditure on:<br>Raising funds<br>-<br>Finance and support 19,516 19,516 18,483<br>-<br>Cost of generating funds 122,819 122,819 119,262<br>-<br>142,335 142,335 137,745<br>Expenditure on charitable activities<br>Glaucoma research 419,313 11,926 431,240 136,094<br>Patient information and support 3,321 673,171 676,492 588,085<br>Professional information and support 11,903 147,752 159,655 112,559<br>-<br>Campaigning and advocacy 63,241 63,241 64,062<br>Cost of glaucoma aids and equipment 681 5,461 6,142 4,107<br>Total expenditure 6 435,219 1,043,888 1,479,106 1,042,652<br>Realised gains on investment assets 12 - - - 480,631<br>Net Income (376,573) 739,289 362,717 1,233,805<br>Unrealised gains on investment assets 12 (110,589) (385,016) (495,605) 524,250<br>Net incoming resources before transfers 7 (487,162) 354,273 (132,888) 1,758,055<br>Gross transfer between funds - - - -<br>Net movement in funds (487,162) 354,274 (132,888) 1,758,055<br>Reconciliation of funds<br>Total funds brought forward 2,081,540 6,210,521 8,292,061 6,534,006<br>Total funds carried forward 1,594,377 6,564,793 8,159,171 8,292,061<br>**----- End of picture text -----**<br>


All of the results above are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 18 to the financial statements. 

Page **37** 



## **Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 


**----- Start of picture text -----**<br>
Charity No 274681<br>Balance sheet Scotland No SC041550<br>Company No. 1293286<br>As at 31 July 2022<br>2022 2021<br>Note £ £<br>Fixed assets<br>Tangible fixed assets 11 16,141 15,888<br>Investments 12 7,052,774 7,071,150<br>Total fixed assets 7,068,915 7,087,038<br>Current assets<br>Stock 13 3,768 4,311<br>Debtors 14 21 1,115,075 308,233<br>Cash at bank and in hand 438,360 1,231,121<br>1,557,202 1,543,665<br>Liabilities<br>Creditors: amounts due within one year 15 20, 21 251,404 249,242<br>Net current assets 1,305,798 1,294,423<br>Total assets less current liabilities 8,374,713 8,381,460<br>Creditors: amounts due after more than one<br>year  16, 21 215,543 89,400<br>Net assets 17 8,159,171 8,292,061<br>Funds 18<br>Restricted funds 1,594,377 2,081,540<br>Unrestricted funds<br>Designated funds 4,482,906 4,482,906<br>General funds 2,081,888 1,727,616<br>Total funds 8,159,171 8,292,061<br>**----- End of picture text -----**<br>


Approved and authorised for issue by the trustees of The International Glaucoma Association 

Page **38** 



## **Glaucoma UK (the operating name of the International Glaucoma Association)** 

## **Statement of cash flow** 


**----- Start of picture text -----**<br>
For the year ended July 2022<br>Cashflows from operating activities: 2022 2021<br>Net cash provided by (used in) operating activities (450,839) 950,872<br>Cashflows from investing activities<br>Dividends and interest from investments 144,749 98,507<br>-<br>Purchase of property, plant and equipment (9,442)<br>Proceeds from sale of investments - 917,254<br>Purchase of investments (492,201) (2,202,236)<br>Net cash provided by (used in)  investing activities (356,894) (1,186,475)<br>Change in cash and cash equivalents in the reporting period (807,733) (235,603)<br>Cash and cash equivalents at the beginning of the reporting<br>period 1,248,827 1,484,430<br>Cash and cash equivalents at the end of the reporting period 441,094 1,248,827<br>Increase/Decrease in cash balances (807,733) (235,603)<br>Reconciliation of net movement in funds to net cash flow from operating activities<br>Net movements in funds for the reporting period (as per the<br>statement of financial activities) (132,888) 1,758,055<br>Adjustments for:<br>Depreciation 9,188 1,977<br>Dividends & interest from investments (144,749) (98,507)<br>Loss/(Profit) on sale of investments 495,605 (1,004,881)<br>(Increase)/Decrease in stocks 542 11<br>(Increase)/Decrease in debtors (806,842) 308,813<br>Increase/(Decrease) in creditors 128,305 (14,595)<br>Net cash provided by (used in) operating activities (450,839) 950,872<br>Analysis of cash and cash equivalents<br>Cash in hand 438,360 1,231,121<br>Investments Capital account 2,734 17,706<br>441,094 1,248,827<br>**----- End of picture text -----**<br>


Page **39** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **1. Accounting policies** 

- a) The financial statements have been prepared under the historical cost convention, as modified by the revaluation of fixed asset investments, and in accordance with applicable accounting standards and the Companies Act 2006. They follow the recommendations in the Statement of Recommended Practice, Accounting and Reporting by Charities. The accounting standards policies have been prepared under Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice) and SORP 2019.The Trustees confirm that the charitable company is a public benefit entity. The accounts are prepared in sterling pound and rounded to the nearest £1.The charity is a company limited by guarantee from 543 voting members incorporated on 15 July 1976 and registered as a charity on 20 December 1977. The objects of the charity are defined by its Articles of Association updated in March 2012. The International Glaucoma Association (IGA) is constituted both as a charity and as a company limited by guarantee and as such the members of its council are directors for the purposes of company law and trustees of the charity for the purposes of charity law. The powers of the council and the permitted activities of the association are described in its governing document, which is the Articles of Association. The International Glaucoma Association registered office is Woodcote House, 15 Highpoint Business Village, Henwood, Ashford, Kent, TN24 8DH. 

In assessing the charity's status as a going concern, the Trustees have considered a range of information in relation to the financial year ahead, including the current status of the pandemic, the impact of the war in Ukraine on the UK economy, the charity's cash resources and known liabilities. Although the macro-economic situation is volatile and deemed to pose some risk to fundraised income, corporate support and rising staff costs, the trustees consider the charity to have adequate resources to continue operating an effective service for at least 12 months ahead and to meet its obligations as they fall due. The financial statements have therefore been prepared on a going concern basis. 

- b) Voluntary income received by way of subscriptions, donations and gifts are included in full in the statement of financial activities when receivable. 

- Income from legacies is accounted for on a receivable basis, recognised when entitlement to the income has been 

- c) established and it is probable that Glaucoma UK will receive the amounts ascertained. This treatment is within SORP 2019 and Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). 

Sales income represents sale of goods excluding VAT where appropriate. 

Investment income is accounted for on an accruals basis. 

- d) Restricted funds are to be used for specific purposes as laid down by the donor.  Expenditure which meets these criteria is charged to the fund. 

- e) Unrestricted funds are donations and other incoming resources received or generated for general charitable purposes. 

- f) Designated funds are unrestricted funds earmarked by the Board of Trustees for particular purposes. Within these funds is money awarded as grants, funding a range of research projects to develop more effective methods of glaucoma diagnosis and treatment. 

g) Costs of generating funds relates to the costs incurred in fundraising activities. 

- h) Critical accounting judgements are used within these accounts as follows: 

   - Residual legacy income debtors are valued at 85% of the expected value of the legacy when certain criteria are met and receipt is probable. 

The support and governance costs are re-apportioned by staff time as explained in note (i). The staff costs attributed to each activity are reviewed each year when the new budget is set. 

- i) Resources expended are recognised in the period in which they are incurred.  Resources expended include attributable VAT which cannot be recovered. 

- Resources expended are allocated to a particular activity where the cost relates directly to that activity.  However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function which includes finance and support and governance is apportioned on the following basis which is an estimate based on staff time of the amount attributable to each activity. 

Support costs Cost of generating funds 11% Expenditure on charitable activities 85% Research 3% 

Page **40** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **1. Accounting policies (continued)** 

- j) Grants awarded are charged to the Statement of Financial Activities in the year in which they are awarded and are subject to receipt of progress reports. 

- k) Governance costs are the costs associated with the governance of the charity, including constitutional and statutory requirements and costs associated with the strategic management of the charity’s activities. 

- l) Monetary assets and liabilities in foreign currencies are translated into sterling at the Bank of England exchange rate for that day. 

- m) Investments held as fixed assets are revalued at market value at the balance sheet date. The Trustees consider that market value is a reasonably accurate representation of the fair value. The gain or loss for the period is taken to the statement of financial activities. 

- n) The fixed assets are held at cost less depreciation and any impairment. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows: 

Fixtures, fittings and equipment 20% Computers 33% 

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use. 

- o) Stocks are stated at the lower of cost and net realisable value.  In general, cost is determined on a first in first out basis.  Net realisable value is the price at which stocks can be sold in the normal course of business after allowing for the costs of realisation.  Provision is made where necessary for obsolete, slow moving and defective stock. During the year the charity received donated items that have been stated at fair value. 

- p) The charity contributes to a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. Contributions payable are charged as an expense in the SOFA (Statement of financial activities) within staff costs then shared between the SOFA categories by staff time within these activities. 

- q) Financial instruments assets and liabilities are valued in the accounts at fair value and are subsequently carried at amortised cost shown in Note 21. 

- R) Debtors are stated at their net realisable value after allowing for bad and doubtful debts. The recoverability of debtors is reviewed at year end and provision is made, either general or specific, based on value, age and composition of our year end debtor balance. 

Page **41** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **2. Voluntary income** 

|||**2022**|2021|**2022**|2021|**2022**|2021|
|---|---|---|---|---|---|---|---|
|||**Restricted**|Restricted|**Unrestricted**|Unrestricted|**Total**|Total|
|||£||£||**£**|£|
||Donations and subscriptions|**4,239**|16,474|**174,354**|175,074|**178,593**|191,548|
||Corporate donations|**-**|-|**1,841**|27,000|**1,841**|27,000|
||Legacies|**6,926**|-|**1,484,027**|1,412,867|**1,490,953**|1,412,867|
||Total|**11,165**|16,474|**1,660,222**|1,614,941|**1,671,388**|1,631,415|
|**3. **|**Investment income**|||||||
||Interest|**2022**<br>**Restricted**<br>£<br>**-**|2021<br>Restricted<br>-|**2022**<br>**Unrestricted**<br>**£**<br>**79**|2021<br>Unrestricted<br>338|**2022**<br>**Total**<br>**£**<br>**79**|2021<br>Total<br>£<br>338|
||Dividends from UK companies|**33,072**|19,227|**111,598**|59,011|**144,670**|78,238|
||Dividends from overseas companies|**-**|4,807|**-**|15,124|**-**|19,931|
||Total|**33,072**|24,034|**111,678**|74,473|**144,749**|98,507|
||**Incoming resources from charitable**|||||||
|**4.**|**activities**|||||||
||Glaucoma aids and equipment sales|**2022**<br>**Restricted**<br>£<br>**-**|2021<br>Restricted<br>£<br>20|**2022**<br>**Unrestricted**<br>£<br>**4,654**|2021<br>Unrestricted<br>£<br>4,193|**2022**<br>**Total**<br>**£**<br>**4,654**|2021<br>Total<br>£<br>4,213|
||UKEGS (UK & EIRE Glaucoma Society)|**-**|9,703|**-**|-|**-**|9,703|
||Other income|**-**|435|**6,561**|4,159|**6,561**|4,594|
||Grants received*|14,409|28,026|62|19,368|**14,471**|47,394|
|||**14,409**|**38,184**|**11,277**|**27,719**|**25,686**|**65,903**|
|**5. **|**Grants received***|**2022**|2021|**2022**|2021|**2022**|2021|
||National government grant - HMRC|**Restricted**<br>£|Restricted<br>£|**Unrestricted**<br>£|Unrestricted<br>£|**Total**<br>**£**|Total<br>£|
||furlough scheme|**-**|-|**62**|19,368|**62**|19,368|
||Professor of Ophthalmology for Glaucoma|||||||
||and Allied Studies at UCL|**15,551**|11,480|**-**|-|**15,551**|11,480|
||UKEGS (UK & EIRE Glaucoma Society)|||||||
||grant|**-**|-|**-**|-|**-**|-|
||The National Lottery - Community Fund **|**(1,142)**<br>**14,409**|16,546<br>**28,026**|**-**<br>**62**|**19,368**|**(1,142)**<br>**14,471**|16,546<br>**47,394**|



> ** The National Lottery - Community fund had an underspend during the year which was paid back to the National Lottery 

Page **42** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **6. Total Expenditure** 

|Staff costs (Note 8)<br>Research grants (Note 9)<br>Regional outreach & helpline<br>Glaucoma aids & equipment<br>Awareness events, PR, social media & volunteering<br>AGM, annual lectures & trustee expenses<br>Fundraising<br>Premises & administration<br>Finance & professional<br>Expenditure<br>Finance & support reallocated<br>Expenses including Finance & Support<br>Governance reallocated<br>**Total Expenditure**|**Cost of**<br>**generating**<br>**funds**<br>**Patient**<br>**information and**<br>**support**<br>**Professional**<br>**information and**<br>**support**<br>**Campaigning and**<br>**advocacy**<br>**Glaucoma**<br>**research**<br>**Finance and**<br>**support**<br>**Governance**<br>**2022 Total**<br>2021 Total<br>£<br>£<br>£<br>£<br>£<br>**£**<br>£<br>60,659<br>336,361<br>88,494<br>33,844<br>17,361<br>99,608<br>28,770<br>**665,097**<br>**582,119**<br>-<br>-<br>-<br>-<br>364,945<br>-<br>-<br>**364,945**<br>**121,236**<br>-<br>16,721<br>291<br>-<br>-<br>93<br>-<br>**17,105**<br>**16,469**<br>1,332<br>3,694<br>1,116<br>-<br>-<br>-<br>-<br>**6,142**<br>**4,107**<br>-<br>6,057<br>5,919<br>5,911<br>-<br>-<br>-<br>**17,887**<br>**21,569**<br>-<br>4,536<br>-<br>-<br>-<br>-<br>5,924<br>**10,460**<br>**8,120**<br>20,066<br>-<br>-<br>-<br>-<br>-<br>-<br>**20,066**<br>**33,585**<br>-<br>78,223<br>3,437<br>-<br>5<br>118,302<br>-<br>**199,967**<br>**179,791**<br>19,516<br>1,177<br>104<br>-<br>36,881<br>72,138<br>47,620<br>**177,436**<br>**75,656**<br>101,573<br>446,769<br>99,361<br>39,755<br>419,192<br>290,141<br>82,314<br>**1,479,106**<br>1,042,652<br>31,123<br>172,580<br>45,404<br>17,365<br>8,909<br>(290,141)<br>14,760<br>132,696<br>619,349<br>144,765<br>57,120<br>428,100<br>-<br>97,074<br>**1,479,106**<br>1,042,652<br>10,971<br>60,836<br>16,006<br>6,121<br>3,140<br>-<br>(97,074)<br>**143,667**<br>**680,186**<br>**160,771**<br>**63,241**<br>**431,240**<br>**-**<br>**-**<br>**1,479,106**<br>1,042,652|
|---|---|



Page **43** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **7. Net (outgoing)/incoming resources** 

This is stated after charging/crediting: 

|Depreciation charge for the year - owned assets<br>Auditors' remuneration:<br>audit<br>other services<br>Trustees expenses<br>Investment managers fee|**2022**<br>**£**<br>**9,188**<br>**2,270**<br>**-**<br>**1,700**<br>**15,029**|2021<br>£<br>1,977<br>3,778<br>-<br>-<br>24,226|
|---|---|---|



Trustees expenses represent the travel and subsistence costs of 7 trustees for 5 meetings £1,700 (2021:0). Within 2022 some Trustees meetings are still held virtually. All meetings were held as virtual meetings and no Trustee expenses for 2021. 

During the accounting year unclaimed Trustees expenses totalled £247 (2021: £0.00). Donations totalling £645 were received from Trustees, (2021: £450). 

No Trustees received remuneration for their services during the financial year. 

The investment managers fee has decreased as the funds are now held within the investment companies charity managed fund which is cheaper to administer 

## **8. Staff costs and numbers** 

Staff costs were as follows: 

|Salaries and wages<br>Social security costs<br>Pension contributions|**2022**<br>**£**<br>**578,325**<br>**57,936**<br>**28,836**<br>**665,097**|2021<br>£<br>510,607<br>48,237<br>23,275<br>582,119|
|---|---|---|



Only one member of key management personnel earned £60,000 or more in the year. A mid-year change of personnel meant that the post was held by two different individuals during the year. The employee earning £60,000 - £70,000 left in January and the position was filed in April by employee earning £70,000 - £80,000. 

||**2022**|2021|
|---|---|---|
||**No.**|No.|
|£60,000 - £70,000|**1**|1|
|£70,000- £80,000|**1**|0|



Pension contributions in respect of the above £60,000 full-time employee totalled £4,805 (2021: £3,335). NI contributions in respect of the above £60,000-£70,000 employee totalled £12,640 (2021: £8,218) The calculated unspent staff holiday entitlement at year end was £12,647, (2021: £10,745). 

The charity contributes to a Royal London defined contribution pension scheme for employees. 

The Chief Executive Officer is the sole key management personnel having authority and responsibility for planning, directing and controlling the activities of Glaucoma UK. 

The management remuneration policy considers the following factors: 

cost of living, pay comparability, affordability, sustainability, and appropriateness. The ratio between the highest and lowest salary should be below 4.5:1 and the ratio between the highest and median (midpoint) salary below 3.5:1. As at 1 August 2022 these ratios were 3.7:1 and 2.3:1 respectively. 

Page **44** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **8. Staff costs and numbers (continued)** 

The average weekly number of employees (full-time equivalent) during the year was: 

|-<br>Cost of generating funds<br>Patient information and support<br>Professional information and support<br>Campaigning and awareness<br>Research<br>Governance<br>Finance and Support costs|**2022**<br>**No.**<br>**1.45**<br>**9.61**<br>**2.18**<br>**0.95**<br>**0.30**<br>**0.58**<br>**2.23**<br>**17.30**|2021<br>No.<br>1.83<br>8.50<br>1.67<br>1.00<br>0.20<br>0.50<br>2.58<br>16.28|
|---|---|---|



The actual number of staff (including part time and full time) in 2022 was 23  (2021: 20)  at year end. 

## **9. Grants Awarded** 

|Fight for Sight<br>University Hospital of Wales<br>Nottingham University Hospital Trust *<br>University of Bradford<br>University College London<br>Ulster University<br>Edinburgh University<br>Cardiff University<br>Grants underspent by researchers<br>University College London's Institute of Ophthalmology - Glaucoma UK<br>Chair Fund|**2022**<br>2021<br>**65,523**<br>52,447<br>**1,500**<br>20,479<br>**-**<br>(60,684)<br>**57,301**<br>-<br>**-**<br>48,380<br>**-**<br>49,811<br>**99,910**<br>-<br>**45,271**<br>-<br>**98,000**<br>-<br>**(2,561)**<br>-<br>**364,945**<br>110,433|
|---|---|



These grants were awarded in accordance with the Glaucoma UK grants policy, and were awarded to fund research into the diagnosis and treatment of glaucoma. 

The negative figure represents an underspend by researchers on grants awarded in previous years. 

## **Conflict of Interest - Grant** 

* Charity Commission approval was sought and received during the year in relation to a research grant award to Nottingham University Hospitals Trust for which Glaucoma UK Chairman - Professor Anthony King - will be the lead researcher. 

## **10. Taxation** 

The charity is exempt from corporation tax and income tax as all its income is charitable and is applied for charitable purposes. 

Page **45** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **11. Tangible fixed assets** 

|**Cost**<br>At the start of the year<br>Additions in year<br>Disposals in year<br>At the end of the year<br>**Depreciation**<br>At the start of the year<br>Charge for the year<br>Disposals in year<br>At the end of the year<br>**Net book value**<br>**At the end of the year**<br>At the start of the year<br>**12.**<br>**Investments**<br>Rathbones Core Investments fund for charities<br>At 1st August 2021<br>Additions at historic cost<br>Disposal proceeds<br>Realised gains<br>Unrealised gains<br>Market value at the end of the year<br>Cash held as part of portfolio<br>Total||Computer<br>equipment<br>£<br>27,743<br>9,442<br>-<br>37,185<br>11,856<br>9,188<br>-<br>21,044<br>**16,141**<br>15,887<br>**2022**<br>**£**<br>**7,053,444**<br>**492,201**<br>**-**<br>**-**<br>**(495,605)**<br>**7,050,040**<br>**2,734**<br>**7,052,774**|<br>**Total**<br>**£**<br>**27,743**<br>**9,442**<br>**-**<br>**37,185**<br>**11,856**<br>**9,188**<br>**-**<br>**21,044**<br>**16,141**<br>15,887<br>2021<br>£<br>4,763,579<br>2,202,238<br>(917,254)<br>480,631<br>524,250<br>7,053,444<br>17,706<br>7,071,150|
|---|---|---|---|



Page **46** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **12. Investments continued** 

Investment management costs were £15,028.67 (£24,226.07 -  2021) 

Glaucoma UK Ltd, Glaucoma International Ltd, Glaucoma Europe Ltd, and Glaucoma Association Ltd are dormant companies historically held by Glaucoma UK (the operating name of the International Glaucoma Association Limited) in order to protect the company identity and to give future flexibility in terms of the charity name. International Glaucoma Association hold 100% of all the dormant companies. 

Glaucoma UK Limited number 04323894 total shareholder funds £1. Glaucoma Europe Limited number 04591043 total shareholders funds £1. Glaucoma International Limited number 04323990 total shareholders funds £1. Glaucoma Association Ltd number 05316092 shareholders funds £1. 

## **13. Stock** 

|Goods for resale<br>**14.**<br>**Debtors**<br>Trade debtors<br>Legacy debtors<br>Prepayments and accrued income<br>VAT debtor<br>Doubtful debt provision|**2022**<br>**£**<br>**3,768**<br>**2022**<br>**£**<br>**38,823**<br>**1,084,911**<br>**20,807**<br>**3,597**<br>**(33,062)**<br>**1,115,075**|2021<br>£<br>4,311<br>2021<br>£<br>**25,241**<br>**266,590**<br>**16,402**<br>**-**<br>**-**<br>**308,233**|
|---|---|---|



Page **47** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **15. Creditors: amounts due within one year** 

|Trade creditors<br>Funds held as agent<br>Accruals & Deferred income<br>Obligations under grant agreements<br>National Insurance|**2022**<br>2021<br>**£**<br>£<br>**43,173**<br>124,735<br>**123,857**<br>87,627<br>**24,514**<br>22,578<br>**59,690**<br>13,050<br>**171**<br>1,253<br>**251,404**<br>249,242|
|---|---|



Funds held as agent represent those held for UKPGS, for which Glaucoma UK provides administration and infrastructure support as shown in note 20. 

**16. Creditors: amounts due after one year** 

|Investments<br>amounts falling due after<br>more than one year<br>Obligations under grant agreements<br>Creditors:<br>**Analysis of net assets between**<br>**funds**<br>Tangible fixed assets<br>Net current assets<br>**Net assets at the end of the year**|Restricted<br>funds<br>£<br>-<br>1,594,377<br>-<br>-<br>**1,594,377**|**2022**<br>2021<br>**£**<br>£<br>**215,543**<br>89,400<br>**215,543**<br>89,400<br> <br>General<br>funds<br>**Total funds**<br>£<br>£<br>**£**<br>-<br>16,141<br>**16,141**<br>4,482,906<br>975,491<br>**7,052,774**<br>-<br>1,305,798<br>**1,305,798**<br>-<br>(215,543)<br>**(215,543)**<br>**4,482,906**<br>**2,081,888**<br>**8,159,171**<br>Designated<br>funds|
|---|---|---|



## **17. Analysis of net assets between funds** 

Page **48** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

|**18.**<br>**Restricted funds:**<br>Research  fund<br>Folkestone Fund<br>London fund<br>Scottish Optom fund<br>UK & Eire Glaucoma Society<br>Digital Support fund<br>**Total restricted funds**<br>**Unrestricted funds:**<br>_Designated funds:_<br>_Total designated funds_<br>General funds<br>**Total unrestricted funds**<br>Income Endowment<br>**Total funds**<br>Research investment fund<br>Children and Young people's Support<br>fund<br>Equipment Replacement and<br>Infrastructure Fund<br>North East fund<br>Compliance Project fund<br>Chair fund<br>**Movements in funds**|At the start<br>of the year<br>Transfers<br>**At the end of**<br>**the year**<br>£<br>£<br>£<br>£<br>£<br>**£**<br>1,657,900<br>49,823<br>(102,404)<br>(110,589)<br>-<br>**1,494,729**<br>15,724<br>-<br>(2,648)<br>-<br>-<br>**13,076**<br>1,239<br>-<br>(1,238)<br>-<br>-<br>**-**<br>315,873<br>9,965<br>(316,909)<br>-<br>-<br>**8,929**<br>3,733<br>-<br>-<br>-<br>-<br>**3,733**<br>8,900<br>-<br>(116)<br>-<br>-<br>**8,784**<br>7,577<br>-<br>-<br>-<br>-<br>**7,577**<br>9,321<br>-<br>-<br>-<br>-<br>**9,321**<br>60,131<br>-<br>(11,903)<br>-<br>-<br>**48,228**<br>1,142<br>(1,142)<br>-<br>-<br>-<br>**-**<br>**2,081,540**<br>**58,646**<br>**(435,219)**<br>**(110,589)**<br>**-**<br>**1,594,377**<br>22,906<br>-<br>-<br>-<br>-<br>**22,906**<br>460,000<br>-<br>-<br>-<br>-<br>**460,000**<br>4,000,000<br>-<br>-<br>-<br>-<br>**4,000,000**<br>4,482,906<br>-<br>-<br>-<br>-<br>**4,482,906**<br>1,727,616<br>1,783,176<br>(1,043,888)<br>(385,016)<br>-<br>**2,081,888**<br>**6,210,521**<br>**1,783,176**<br>**(1,043,888)**<br>**(385,016)**<br>**-**<br>**6,564,793**<br>**8,292,061**<br>**1,841,822**<br>**(1,479,107)**<br>**(495,605)**<br>**-**<br>**8,159,171**<br>Other gains<br>and losses<br>Incoming<br>resources<br>Outgoing<br>resources|
|---|---|



Page **49** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

**For the year ended 31 July 2022** 

## **18. Movements in Funds (continued)** 

## **Purposes of restricted funds** 

The Chair fund is used to fund the post of Professor of Ophthalmology for Glaucoma and Allied Studies at University College London. 

The North East fund was established following receipt of a legacy and is restricted to supporting our work in the North East of England. 

The Compliance Project fund was granted by pharmaceutical companies to provide demonstration and educational eye drop materials. 

The Research fund represents donations and charitable trust income received specifically to fund glaucoma research. The fund was drawn on throughout the year as detailed on Note 9. 

The Folkestone fund comprises legacy income restricted to work in Folkestone. 

The Children and Young People's Support fund comprises income donated for services for young people affected by glaucoma and their families and carers. It aims to help us better understand their particular support needs and deliver appropriate services in response. 

The London fund is restricted to the London area, and has been used mainly for awareness raising and support work with BAME communities at greatest risk of glaucoma sight loss. 

The Scottish Optom training fund is charitable trust income earmarked for eye drop adherence training for optometrists across Scotland. Following delays due to Covid-19 and changes to the professional training landscape in the intevening period work is ongoing to identify the best possible use of the grant funding, while still meeting - and we hope exceeding - the funding objectives. 

The UKEGS fund comprises money for the work of the United Kingdom and Eire Society (UKEGS), a national scientific society that operates under the aegis of Glaucoma UK. 

The Digital support fund was received from national lottery community fund to be spent within 6 months on the Glaucoma UK Digital care and support project. The £1,142 underspend on the Digital support fund has been returned to the national lottery. 

The designated income endowment fund represents the donation of shares which form the basis of a stock market portfolio, which will eventually provide for the running costs of the association. 

The designated Equipment Replacement and Infrastructure fund is held to cover the cost of equipment replacement, infrastructure development, premises costs and dilapidations. 

The designated Research Investment fund aims to produce a reliable income stream specifically to fund the charity's research priorities in the years ahead. 

Page **50** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

## **Notes to the financial statements** 

## **For the year ended 31 July 2022** 

## **19. Operating lease commitments** 

The charity had annual commitments at the year end under operating leases expiring as follows: 

|**Operating lease commitments**<br>The charity had annual commitments at the year end under operating leases|expiring as follows:||
|---|---|---|
||Property||
||**2022**|2021|
||**£**|£|
|Within one year|**34,000**|**34,000**|
|Within 1 -2 Years|**34,000**|**68,000**|
|The total future minimum lease payment is £68,000|||



## **20. Related Parties** 

Included in Note 15 are funds due to related parties held for the UK Paediatric Glaucoma Society (UKPGS) of which we provide administration and infrastructure support. One Glaucoma UK Trustee is also a UKPGS trustee during the financial year. 

|**Financial Statement of UKPGS**<br>Income<br>Expenditure<br>Closing balance<br>Balance brought forward<br>Total funds held|**2022**<br>2021<br>**£**<br>£<br>**12,030**<br>11,920<br>**(10,093)**<br>(14,882)<br>**1,937**<br>(2,962)<br>**22,578**<br>25,540<br>**24,514**<br>22,578|
|---|---|



Included in Note 9 Grants awarded is a Related party transaction being grant awarded to Nottingham University Hospitals Trust for which Glaucoma UK Chairman Professor Anthony King will be the lead researcher. The balance outstanding to this grant is £57,301 which is the full grant awarded. 

**21. Financial Instruments** 

Financial Debt instruments 

|Trade debtors<br>Legacy debtors<br>Prepayments and accrued income<br>VAT debtor<br>Bad debt provision<br>Trade creditors<br>Obligations under grant agreements<br>Funds held as agent<br>Accruals<br>National Insurance<br>measured at amortised cost<br>Financial instruments measured at<br>amortised cost|**2022**<br>2021<br>**£**<br>£<br>**38,823**<br>25,241<br>**1,084,911**<br>266,590<br>**20,807**<br>16,402<br>**3,597**<br>-<br>**(33,062)**<br>-<br>**1,115,075**<br>308,233<br>**43,173**<br>124,735<br>**339,400**<br>177,027<br>**24,514**<br>22,578<br>**59,690**<br>13,050<br>**171**<br>1,253<br>**466,947**<br>338,643|
|---|---|



Page **51** 



**Glaucoma UK (the operating name of the International Glaucoma Association Limited)** 

**For the year ended 31 July 2022** 

## **Notes to the financial statements** 

## **22. Covid-19 pandemic and cost of living impact** 

The trustees report that during the financial year ended 31st July 2022, face-to-face activity levels in the early months were constrained by concerns of a further wave of Covid-19.  Extensions were also granted to a number of ongoing research projects following delays caused by the pandemic.  However, helpline support and online provision (including digital support groups) were largely unaffected.  The war in Ukraine and the resultant impact on the UK economy was felt in a reduction in donations, subscriptions and corporate support, as well as a diminution in the value of the investment portfolio. The trustees anticipate that the operating environment will continue to be challenging throughout 2022-23, but are confident that sufficient financial reserves are in place to continue to offer all existing services and pursue planned activities for growth in the coming year. 

Page **52**